Terence Flynn
Stock Analyst at Morgan Stanley
(4.24)
# 390
Out of 5,182 analysts
251
Total ratings
56.39%
Success rate
13.18%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $612 → $616 | $429.82 | +43.32% | 6 | May 5, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $270 → $278 | $201.55 | +37.93% | 21 | Apr 30, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $11 → $15 | $14.09 | +6.46% | 6 | Apr 28, 2026 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $471 → $519 | $564.94 | -8.13% | 12 | Apr 10, 2026 | |
| RPRX Royalty Pharma | Maintains: Overweight | $61 → $63 | $50.79 | +24.04% | 14 | Apr 10, 2026 | |
| PFE Pfizer | Maintains: Equal-Weight | $27 → $28 | $25.68 | +9.03% | 22 | Apr 10, 2026 | |
| JNJ Johnson & Johnson | Maintains: Overweight | $262 → $267 | $221.32 | +20.64% | 29 | Apr 10, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,313 → $1,327 | $948.45 | +39.91% | 25 | Apr 10, 2026 | |
| BNTX BioNTech SE | Maintains: Overweight | $125 → $126 | $94.13 | +33.86% | 7 | Apr 10, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $309 → $326 | $331.70 | -1.72% | 13 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $38 | $23.66 | +60.61% | 4 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $23 → $20 | $25.36 | -21.14% | 9 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $36 | $16.52 | +117.92% | 7 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $21 | $9.86 | +112.98% | 5 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $37 | $56.16 | -34.12% | 12 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $102 | $111.38 | -8.42% | 20 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $39.10 | +219.69% | 2 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $9 | $13.35 | -32.58% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $10.11 | +8.80% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $54.83 | -41.64% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.95 | +171.19% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $193.45 | +125.38% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $295.05 | - | 2 | Oct 2, 2017 |
Vertex Pharmaceuticals
May 5, 2026
Maintains: Overweight
Price Target: $612 → $616
Current: $429.82
Upside: +43.32%
AbbVie
Apr 30, 2026
Maintains: Overweight
Price Target: $270 → $278
Current: $201.55
Upside: +37.93%
Intellia Therapeutics
Apr 28, 2026
Maintains: Equal-Weight
Price Target: $11 → $15
Current: $14.09
Upside: +6.46%
United Therapeutics
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $471 → $519
Current: $564.94
Upside: -8.13%
Royalty Pharma
Apr 10, 2026
Maintains: Overweight
Price Target: $61 → $63
Current: $50.79
Upside: +24.04%
Pfizer
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $27 → $28
Current: $25.68
Upside: +9.03%
Johnson & Johnson
Apr 10, 2026
Maintains: Overweight
Price Target: $262 → $267
Current: $221.32
Upside: +20.64%
Eli Lilly and Company
Apr 10, 2026
Maintains: Overweight
Price Target: $1,313 → $1,327
Current: $948.45
Upside: +39.91%
BioNTech SE
Apr 10, 2026
Maintains: Overweight
Price Target: $125 → $126
Current: $94.13
Upside: +33.86%
Amgen
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $309 → $326
Current: $331.70
Upside: -1.72%
Mar 20, 2026
Maintains: Overweight
Price Target: $33 → $38
Current: $23.66
Upside: +60.61%
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $20
Current: $25.36
Upside: -21.14%
Jan 8, 2026
Upgrades: Overweight
Price Target: $15 → $36
Current: $16.52
Upside: +117.92%
Jan 6, 2026
Maintains: Overweight
Price Target: $26 → $21
Current: $9.86
Upside: +112.98%
Dec 12, 2025
Maintains: Underweight
Price Target: $36 → $37
Current: $56.16
Upside: -34.12%
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $100 → $102
Current: $111.38
Upside: -8.42%
Dec 12, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $39.10
Upside: +219.69%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $13.35
Upside: -32.58%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $10.11
Upside: +8.80%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $54.83
Upside: -41.64%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.95
Upside: +171.19%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $193.45
Upside: +125.38%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $295.05
Upside: -